Hepatitis Therapeutics Market cover

Hepatitis Therapeutics Market by Disease Types (Hepatitis A, Hepatitis B, Hepatitis C, and Others [Hepatitis D and Hepatitis E]) and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028

  • Report ID: CG-2177
  • Author: Growth Market Reports
  • Rating: 4.9
  • Total Reviews: 4
  • No. Of Pages: 193
  • Format:
  • Pub. Date: Upcoming
  • Share:

The global hepatitis therapeutics market size is anticipated to expand at a high CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the rising cases of autoimmune illnesses, the increasing incidence of viral hepatitis, and rising global healthcare spending.

Hepatitis Therapeutics Market summary

When inflammation occurs in the liver of an individual, it is known as hepatitis. This disease is commonly caused due to the hepatitis virus; however, other reasons for causing hepatitis are autoimmune diseases, infections, medication errors, and toxic substances including drugs, alcohol, and others. Globally, over 1.34 million individuals died as a result of this disease in 2015. The number of death caused by HIV and tuberculosis are significantly less in number when compared to the number of deaths caused by hepatitis. The number of deaths caused by HIV and tuberculosis, on the other hand, is decreasing, but the rate of death caused by viral hepatitis is increasing.  According to the World Health Organization, approximately 1.4 million individuals die each year from hepatitis, and around 400 million people are infected with at least one form of the disease.

This ailment is divided into two forms based on the length of time the patient is afflicted. When this condition lasts less than six months, it is classed as acute; when it lasts longer than six months, it is classified as chronic. Hepatitis A Virus (HAV) is transferred through drinking contaminated water, eating contaminated food, or coming into touch with an infected individual. According to the estimations of WHO, 90 percent of children in developing nations are infected with the virus before they reach the age of ten, owing to insufficient hygiene and sanitation.

Market Trends, Drivers, Restraints, and Opportunities

  • Increasing patient awareness about advanced therapeutics and making improvements to healthcare facilities are anticipated to boost the market growth during the forecast period.
  • Introduction and emergence of generic versions of hepatitis C virus (HCV) medicines in the market is estimated to drive the market over the forecast period.
  • The expiration of the patent on the branded version of the drug, as well as the side effects of the drug, resulted in the drug's discontinuation is anticipated to hinder the market growth.
  • Due to high medicine prices, access to therapies for this disease has been limited to individuals with a high-income level, which may function as a constraining factor for this market.
  • Emerging markets and significant investment in R&D activities are expected to present key opportunities for the market growth.

Scope of the Report

The report on the global hepatitis therapeutics market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes

Details

Report Title

Hepatitis Therapeutics Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast

Base Year

2020

Historic Data

2018–2019

Forecast Period

2021–2028

Segmentation

Disease Types (Hepatitis A, Hepatitis B, Hepatitis C, and Others [Hepatitis D and Hepatitis E])

Regional Scope

Asia Pacific, North America, Latin America, Europe, and Middle East & Africa

Report Coverage

Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast

Key Players Covered in the Report

Johnson & Johnson; Gilead; Merck & Co., Inc.; Bristol-Myers Squibb Company; and AbbVie Inc.

Market Segment Insights

Hepatitis B segment is projected to account for a large market share

Based on disease types, the hepatitis therapeutics is segmented into hepatitis A, hepatitis B, hepatitis C, and others. The others segment is further segmented into hepatitis D and hepatitis E.  Hepatitis B segment is segment is projected to account for a large market share during the forecast period owing to the high prevalence of hepatitis B. To replicate and proliferate in the body, the Hepatitis D virus (HDV) requires the assistance of the hepatitis B virus (HBV). The HDV virus is a Ribonucleic Acid virus. Globally, approximately 15 million people are co-infected with HDV and HBV, and no effective HDV medication is currently available. As a result, immunization against HBV is strongly advised in order to prevent both hepatitis B and D. This is one of the primary factors influencing the market's current revenue share.

Hepatitis Therapeutics Market types

HCV causes a variety of major problems as compared to hepatitis A and B. HCV infects around 130 to 150 million persons worldwide, according to the estimations of WHO. Furthermore, a large percentage of HCV-infected patients develop liver cirrhosis or cancer, and approximately 700,000 individuals die as a result of these diseases. The above-mentioned factor is expected to drive the demand for HCV medications in the coming years. One of the primary drivers contributing to the market growth is the introduction of technologically enhanced medicinal solutions for the treatment of hepatitis. Hepatitis C was previously incurable, but with the advent of drugs like Sovaldi and Harvoni in 2013 and 2014, respectively, the treatment rate has risen dramatically in recent years. According to reports, these treatments sold for more than USD 19.1 billion in 2015, and demand for these drugs is projected to stay robust in the coming years.

Asia Pacific is anticipated to dominate the market

On the basis of regions, the hepatitis therapeutics market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. Asia Pacific is anticipated to dominate the market during the forecast period. The regional market growth can be attributed to increased disease burden, increased access to medications, improved healthcare and sanitation, and increased knowledge about hepatitis vaccines. North America is expected to lead the hepatitis therapies market, followed by Europe and Asia Pacific. The North American market accounted for more than 40.2% of revenue in 2019 owing to high demand in the United States, somewhat lower patient affordability, and increased awareness of advanced treatments in the region. Some of the important factors contributing to the high share are the presence of favorable reimbursement policies, the availability of well-developed healthcare infrastructure, and access to the latest medicines available for treatment.

Hepatitis Therapeutics Market region

Furthermore, the market in Asia Pacific is expected to be benefited from the rising demand for generic pharmaceuticals. Gilead has granted licenses to seven Indian producers to deliver hepatitis medications to various parts of the world. More than half of the HCV-infected population lives in the countries covered by this agreement. The Medicine Patent Pool's varied licenses allow multiple manufacturers to develop generic versions of these HCV treatments even while the drugs are patented, which is predicted to have an impact on the market over the forecast period due to lower drug prices and higher consumption rates. However, with the high prevalence rates and an increase in the import of generic drugs to treat various hepatitis disorders, the markets in MEA and Latin America are expected to grow rapidly. Different manufacturers are developing their businesses in MEA and Latin America to cater to the large unmet demands for improved treatment as the patient population in the United States and other developed regions declines due to the beneficial results of employing HCV medications.

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Hepatitis Therapeutics Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Hepatitis Therapeutics Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Hepatitis Therapeutics Market - Supply Chain
  4.5. Global Hepatitis Therapeutics Market Forecast
     4.5.1. Hepatitis Therapeutics Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Hepatitis Therapeutics Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. Hepatitis Therapeutics Market Absolute $ Opportunity
5. Global Hepatitis Therapeutics Market Analysis and Forecast by Region
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Region
     5.2.2. Y-o-Y Growth Projections by Region
  5.3. Hepatitis Therapeutics Market Size and Volume Forecast by Region
     5.3.1. North America
     5.3.2. Latin America
     5.3.3. Europe
     5.3.4. Asia Pacific
     5.3.5. Middle East and Africa (MEA)
  5.4. Absolute $ Opportunity Assessment by Region
  5.5. Market Attractiveness/Growth Potential Analysis by Region
  5.6. Global Hepatitis Therapeutics Demand Share Forecast, 2019-2026
6. North America Hepatitis Therapeutics Market Analysis and Forecast
  6.1. Introduction
     6.1.1. Basis Point Share (BPS) Analysis by Country
     6.1.2. Y-o-Y Growth Projections by Country
  6.2. North America Hepatitis Therapeutics Market Size and Volume Forecast by Country
     6.2.1. U.S.
     6.2.2. Canada
  6.3. Absolute $ Opportunity Assessment by Country
  6.4. Market Attractiveness/Growth Potential Analysis
     6.4.1. By Country
     6.4.2. By Product Type
     6.4.3. By Application
  6.5. North America Hepatitis Therapeutics Demand Share Forecast, 2019-2026
7. Latin America Hepatitis Therapeutics Market Analysis and Forecast
  7.1. Introduction
     7.1.1. Basis Point Share (BPS) Analysis by Country
     7.1.2. Y-o-Y Growth Projections by Country
     7.1.3. Latin America Average Pricing Analysis
  7.2. Latin America Hepatitis Therapeutics Market Size and Volume Forecast by Country
      7.2.1. Brazil
      7.2.2. Mexico
      7.2.3. Rest of Latin America
   7.3. Absolute $ Opportunity Assessment by Country
  7.4. Market Attractiveness/Growth Potential Analysis
     7.4.1. By Country
     7.4.2. By Product Type
     7.4.3. By Application
  7.5. Latin America Hepatitis Therapeutics Demand Share Forecast, 2019-2026
8. Europe Hepatitis Therapeutics Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
     8.1.3. Europe Average Pricing Analysis
  8.2. Europe Hepatitis Therapeutics Market Size and Volume Forecast by Country
     8.2.1. Germany
     8.2.2. France
     8.2.3. Italy
     8.2.4. U.K.
     8.2.5. Spain
     8.2.6. Russia
     8.2.7. Rest of Europe
  8.3. Absolute $ Opportunity Assessment by Country
  8.4. Market Attractiveness/Growth Potential Analysis
     8.4.1. By Country
     8.4.2. By Product Type
     8.4.3. By Application
  8.5. Europe Hepatitis Therapeutics Demand Share Forecast, 2019-2026
9. Asia Pacific Hepatitis Therapeutics Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Asia Pacific Average Pricing Analysis
  9.2. Asia Pacific Hepatitis Therapeutics Market Size and Volume Forecast by Country
     9.2.1. China
     9.2.2. Japan
     9.2.3. South Korea
     9.2.4. India
     9.2.5. Australia
     9.2.6. Rest of Asia Pacific (APAC)
  9.3. Absolute $ Opportunity Assessment by Country
  9.4. Market Attractiveness/Growth Potential Analysis
     9.4.1. By Country
     9.4.2. By Product Type
     9.4.3. By Application
  9.5. Asia Pacific Hepatitis Therapeutics Demand Share Forecast, 2019-2026
10. Middle East & Africa Hepatitis Therapeutics Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Middle East & Africa Average Pricing Analysis
  10.2. Middle East & Africa Hepatitis Therapeutics Market Size and Volume Forecast by Country
     10.2.1. Saudi Arabia
     10.2.2. South Africa
     10.2.3. UAE
     10.2.4. Rest of Middle East & Africa (MEA)
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Market Attractiveness/Growth Potential Analysis
     10.4.1. By Country
     10.4.2. By Product Type
     10.4.3. By Application
  10.5. Middle East & Africa Hepatitis Therapeutics Demand Share Forecast, 2019-2026
11. Competition Landscape
  11.1. Global Hepatitis Therapeutics Market: Market Share Analysis
  11.2. Hepatitis Therapeutics Distributors and Customers
  11.3. Hepatitis Therapeutics Market: Competitive Dashboard
  11.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     11.4.1. Johnson & Johnson
     11.4.2. Gilead
     11.4.3. Merck & Co., Inc.
     11.4.4. Bristol-Myers Squibb Company
     11.4.5. AbbVie Inc.

Segments Covered in the Report

The global hepatitis therapeutics market has been segmented on the basis of

Disease Types

  • Hepatitis A
  • Hepatitis B
  • Hepatitis C
  • Others
    • Hepatitis D
    • Hepatitis E

Regions

  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa

Key Players

  • Johnson & Johnson
  • Gilead
  • Merck & Co., Inc.
  • Bristol-Myers Squibb Company
  • AbbVie Inc.

Key players competing in the global hepatitis therapeutics market are Johnson & Johnson; Gilead; Merck & Co., Inc.; Bristol-Myers Squibb Company; and AbbVie Inc. Several manufacturers are constantly engaged to expand their operations in the targeted regions to meet the significant unmet needs of hepatitis patients. Another important business strategy adopted by these market players influencing market expansion is the use of varied pricing models in different areas of the world.

Hepatitis Therapeutics Market keyplayers

Buy Report